First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast Cancer · Solid Tumors, Adult
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 880 (planned)
- Started
- Apr 17, 2023
- Main results expected
- Jul 2030
- Fully finished
- Jul 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)
Measured over: First 28 days of treatment
Proportion of participants who experience at least 1 DLT during the first 28 days of treatment
Measured over: First 28 days of treatment
Objective response rate (ORR) defined as the percentage of participants with partial response or complete response based on RECIST 1.1
Measured over: 12 months
Incidence of TEAEs/SAEs ≥ grade 2
Measured over: 12 months
Frequency of TEAEs according to CTCAE v5.0 criteria
Measured over: 12 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05768139 · record last updated 2026-07-07 · checked 2026-11-09 15:42 UTC